BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Shu L, Zhou X, Pan H, Xu Q, Guo J, Tang B, Sun Q. A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease. Parkinsons Dis 2018;2018:3136415. [PMID: 30363648 DOI: 10.1155/2018/3136415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Riboldi GM, Vialle RA, Navarro E, Udine E, de Paiva Lopes K, Humphrey J, Allan A, Parks M, Henderson B, Astudillo K, Argyrou C, Zhuang M, Sikder T, Oriol Narcis J, Kumar SD, Janssen W, Sowa A, Comi GP, Di Fonzo A, Crary JF, Frucht SJ, Raj T. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease. Mol Neurodegener 2022;17:52. [PMID: 35978378 DOI: 10.1186/s13024-022-00554-8] [Reference Citation Analysis]
2 Smith LJ, Lee C, Menozzi E, Schapira AHV. Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Front Neurol 2022;13:971252. [DOI: 10.3389/fneur.2022.971252] [Reference Citation Analysis]
3 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna) 2022. [PMID: 35932311 DOI: 10.1007/s00702-022-02531-3] [Reference Citation Analysis]
4 Carandina A, Lazzeri G, Rodrigues GD, Franco G, Monfrini E, Arienti F, Frattini E, Trezzi I, da Silva Soares PP, Bellocchi C, Furlan L, Montano N, Di Fonzo A, Tobaldini E. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control. Front Neurosci 2022;16:842498. [DOI: 10.3389/fnins.2022.842498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Leocadi M, Canu E, Donzuso G, Stojkovic T, Basaia S, Kresojević N, Stankovic I, Sarasso E, Piramide N, Tomic A, Markovic V, Petrovic I, Stefanova E, Kostic VS, Filippi M, Agosta F. Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients. J Neurol 2021. [PMID: 34297177 DOI: 10.1007/s00415-021-10713-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
6 Day JO, Mullin S. The Genetics of Parkinson's Disease and Implications for Clinical Practice. Genes (Basel) 2021;12:1006. [PMID: 34208795 DOI: 10.3390/genes12071006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 17.0] [Reference Citation Analysis]
7 Menozzi E, Schapira AHV. Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 2021;12:694764. [PMID: 34248830 DOI: 10.3389/fneur.2021.694764] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
8 Magnusen AF, Hatton SL, Rani R, Pandey MK. Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. Front Neurol 2021;12:636139. [PMID: 34239490 DOI: 10.3389/fneur.2021.636139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
9 Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2021;42:2261-71. [PMID: 33837876 DOI: 10.1007/s10072-021-05230-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
10 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
11 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
12 Verbrugge J, Cook L, Miller M, Rumbaugh M, Schulze J, Heathers L, Wetherill L, Foroud T. Outcomes of genetic test disclosure and genetic counseling in a large Parkinson's disease research study. J Genet Couns 2021;30:755-65. [PMID: 33319432 DOI: 10.1002/jgc4.1366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
14 Di Rocco M, Di Fonzo A, Barbato A, Cappellini MD, Carubbi F, Giona F, Giuffrida G, Linari S, Pession A, Quarta A, Scarpa M, Spada M, Strisciuglio P, Andria G. Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives? Orphanet J Rare Dis 2020;15:262. [PMID: 32967694 DOI: 10.1186/s13023-020-01529-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pan HX, Zhao YW, Mei JP, Fang ZH, Wang Y, Zhou X, Zhou YJ, Zhang R, Zhang KL, Jiang L, Zeng Q, He Y, Wang Z, Liu ZH, Xu Q, Sun QY, Yang Y, Hu YC, Chen YS, Du J, Lei LF, Zhang HN, Wang CY, Yan XX, Shen L, Jiang H, Tan JQ, Li JC, Tang BS, Guo JF. GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson's disease: a two-cohort case-control study. Transl Neurodegener 2020;9:31. [PMID: 32746945 DOI: 10.1186/s40035-020-00212-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
16 Avenali M, Blandini F, Cerri S. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease. Front Aging Neurosci 2020;12:97. [PMID: 32372943 DOI: 10.3389/fnagi.2020.00097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 20.5] [Reference Citation Analysis]
17 Illés A, Csabán D, Grosz Z, Balicza P, Gézsi A, Molnár V, Bencsik R, Gál A, Klivényi P, Molnar MJ. The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Front Genet 2019;10:1061. [PMID: 31737044 DOI: 10.3389/fgene.2019.01061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019;8:E364. [PMID: 31010158 DOI: 10.3390/cells8040364] [Cited by in Crossref: 109] [Cited by in F6Publishing: 115] [Article Influence: 36.3] [Reference Citation Analysis]